Aquestive Therapeutics Q3 2026 Revenue Falls to $7.6 Million
Story updates
10:14:29 PM UTC
SquawkNews
AQUESTIVE THERAPEUTICS, INC.: OUTLOOK FY2026 TOTAL REV $46 MLN TO $50 MLN
Related stories
Spartan Delta Reports Q3 Results, Updates Capital Program and Guidance
Spartan Delta announced third-quarter 2026 results, an updated 2026 capital program, 2027 guidance and a higher Duvernay production target.
M impact | EQUITY | Nov 03, 2026, 11:04 PM UTC
3M Reaches Broad Resolution of AFFF Personal Injury Litigation
M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC
3M to Commit $5.8 Billion Through 2034 to Resolve Injury Claims
3M says it will make a $5.8 billion present-value commitment through 2034 to resolve multidistrict personal injury claims, substantially reducing litigation risk and uncertainty.
M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC
PACS Group Reports Q3 Revenue Growth and Raises 2026 Revenue Guidance
PACS Group reported third-quarter 2026 revenue of $1.50 billion, up 11.5% year over year, and adjusted EPS of $0.63, which surpassed analyst expectations. It raised full-year 2026
M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC
Seadrill Reports Q3 2026 Revenue of $428 Million, Raises Guidance
Seadrill reported a $0.49 per-share loss, versus consensus earnings of $0.19 per share. Revenue was $428.0 million, above the FactSet estimate of $382.7 million.
M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC
Freshworks Reports Third-Quarter Revenue of $245.4 Million, Up 14%
Freshworks reported adjusted EPS of $0.22, above the $0.18 analyst estimate, and revenue above the $245.1 million FactSet estimate. The company also updated its fourth-quarter and
M impact | EQUITY | Nov 03, 2026, 11:03 PM UTC